n-methyl-3,4-methylenedioxyamphetamine has been researched along with Depressive Disorder, Treatment-Resistant in 2 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Depressive Disorder, Treatment-Resistant: Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tullis, P | 1 |
| Pathania, R | 1 |
2 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
How ecstasy and psilocybin are shaking up psychiatry.
Topics: Animals; Certification; Clinical Trials as Topic; Depression; Depressive Disorder, Treatment-Resista | 2021 |
Therapeutic potential of psychedelic agents.
Topics: Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetam | 2015 |